Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

An Interleukin-6 Receptor Polymorphism is Associated with Opisthorchiasis-Linked Cholangiocarcinoma Risk in Thailand

  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

The cholangiocarcinoma (CCA) is a relatively rare cancer worldwide but it is highly prevalent in Thailand where the liver fluke, Opisthorchis viverrini is endemic. There are reports that interleukin 6 (IL-6) may play an important role in the pathogenesis of opisthorchiasis associated CCA. Functionally, IL-6 can act on target cells through its receptor, IL-6R, and IL-6R polymorphisms may affect the functional activity of IL-6 leading to susceptibility to cholangiocarcinogenesis. Therefore, we assessed the association of the 48892 A/C (Asp358Ala) polymorphism in exon 9 of the IL-6R gene in 79 CCA cases compared to 80 healthy controls using the PCR-RFLP technique. The results showed significant differences between CCA cases and controls in overall genotype (p=0.001) and allele frequencies (p=0.0002). Chi-square for trend test revealed a significant association between genotype and CCA susceptibility (p=0.0002). The odds ratios (ORs) for genotype were 0.283 (95% CI=0.131-0.605, AC vs. AA; p=0.0003) and 0.206 (95% CI=0.196-1.245, CC vs. AA; p=0.0416), the OR for alleles was 0.347 (95% CI=0.187-0.633, allele C vs. allele A; p=0.0002) and that for the carrier C variant was 0.272 (95% CI=0.130-0.564; p=0.0001). This study demonstrated a close association between an IL-6R polymorphism, specifically higher A allele, and cholangiocarcinoma.

Keywords

References

  1. Blechacz B, Gores GJ (2008). Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 48, 308-21.
  2. Bouvard V, Baan R, Straif K, et al (2009). A review of human carcinogens--Part B: biological agents. Lancet Oncol, 10, 321-2. https://doi.org/10.1016/S1470-2045(09)70096-8
  3. Bustamante M, Nogues X, Mellibovsky L, et al (2007). Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women. Eur J Endocrinol, 157, 677-84. https://doi.org/10.1530/EJE-07-0389
  4. Dosquet C, Schaetz A, Faucher C, et al (1994), Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer, 30, 162-7. https://doi.org/10.1016/0959-8049(94)90079-5
  5. Esteve E, Villuendas G, Mallolas J, et al (2006). Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol, 65, 88-91. https://doi.org/10.1111/j.1365-2265.2006.02553.x
  6. Galicia JC, Tai H, Komatsu Y, et al (2006). Interleukin-6 receptor gene polymorphisms and periodontitis in a non-smoking Japanese population. J Clin Periodontol, 33, 704-9. https://doi.org/10.1111/j.1600-051X.2006.00978.x
  7. Galicia JC, Tai H, Komatsu Y, et al (2004). Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun, 5, 513-6. https://doi.org/10.1038/sj.gene.6364120
  8. Goydos JS, Brumfield AM, Frezza E, et al (1998). Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg, 227, 398-404. https://doi.org/10.1097/00000658-199803000-00012
  9. Gu F, Qureshi AA, Niu T, et al (2008). Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res, 18, 330-5. https://doi.org/10.1097/CMR.0b013e32830658b2
  10. Heinrich PC, Behrmann I, Haan S, et al (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J, 374, 1-20. https://doi.org/10.1042/BJ20030407
  11. Heinrich PC, Behrmann I, Muller-Newen G, et al (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J, 334, 297-314. https://doi.org/10.1042/bj3340297
  12. Huai JP, Ding J, Ye XH, et al (2014). Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies. Asian Pac J Cancer Prev, 15, 3477-82. https://doi.org/10.7314/APJCP.2014.15.8.3477
  13. Hull J, Campino S, Rowlands K, et al (2007). Identification of common genetic variation that modulates alternative splicing. PLoS Genet, 3, 99. https://doi.org/10.1371/journal.pgen.0030099
  14. IARC (1994). Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum, 61, 121-75.
  15. Jiang CQ, Lam TH, Liu B, et al (2010). Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity, 18, 1969-74. https://doi.org/10.1038/oby.2010.31
  16. Kim LH, Lee HS, Kim YJ, et al (2003). Identification of novel SNPs in the interleukin 6 receptor gene (IL6R). Hum Mutat, 21, 450-1.
  17. Lamas JR, Rodriguez-Rodriguez L, Varade J, et al (2010). Influence of IL6R rs8192284 polymorphism status in disease activity in rheumatoid arthritis. J Rheumatol, 37, 1579-81. https://doi.org/10.3899/jrheum.091455
  18. Mairiang E, Laha T, Bethony JM, et al (2012). Ultrasonography assessment of hepatobiliary abnormalities in 3359 subjects with Opisthorchis viverrini infection in endemic areas of Thailand. Parasitol Int, 61, 208-11. https://doi.org/10.1016/j.parint.2011.07.009
  19. Malhi H, Gores GJ (2006). Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol, 45, 856-67. https://doi.org/10.1016/j.jhep.2006.09.001
  20. Manwong M, Songserm N, Promthet S, et al (2013). Risk factors for cholangiocarcinoma in the lower part of Northeast Thailand: a hospital-based case-control study. Asian Pac J Cancer Prev, 14, 5953-6. https://doi.org/10.7314/APJCP.2013.14.10.5953
  21. Marinou I, Walters K, Winfield J, et al (2010). A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis, 69, 1191-4. https://doi.org/10.1136/ard.2008.100644
  22. Matsumoto K, Onoyama T, Kawata S, et al (2014). Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med, 53, 651-4. https://doi.org/10.2169/internalmedicine.53.1410
  23. Mullberg J, Oberthur W, Lottspeich F, et al (1994). The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol, 152, 4958-68.
  24. Mullberg J, Schooltink H, Stoyan T, et al (1993). The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol, 23, 473-80. https://doi.org/10.1002/eji.1830230226
  25. Ninlawan K, O'Hara SP, Splinter PL, et al (2010). Opisthorchis viverrini excretory/secretory products induce Toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. Parasitol Int, 59, 616-21. https://doi.org/10.1016/j.parint.2010.09.008
  26. Okada S, Okusaka T, Ishii H, et al (1998). Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol, 28, 12-5. https://doi.org/10.1093/jjco/28.1.12
  27. Park J, Tadlock L, Gores GJ, et al (1999). Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology, 30, 1128-33. https://doi.org/10.1002/hep.510300522
  28. Qi L, Rifai N, Hu FB (2007). Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. Women. Diabetes, 56, 3075-81. https://doi.org/10.2337/db07-0505
  29. Reich D, Patterson N, Ramesh V, et al (2007). Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet, 80, 716-26. https://doi.org/10.1086/513206
  30. Shin HR, Oh JK, Masuyer E, et al (2010). Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia. Asian Pac J Cancer Prev, 11, 1159-66.
  31. Sripa B, Brindley PJ, Mulvenna J, et al (2012a). The tumorigenic liver fluke Opisthorchis viverrini-multiple pathways to cancer. Trends Parasitol, 28, 395-407. https://doi.org/10.1016/j.pt.2012.07.006
  32. Sripa B, Kaewkes S, Sithithaworn P, et al (2007). Liver fluke induces cholangiocarcinoma. PLoS Med, 4, e201. https://doi.org/10.1371/journal.pmed.0040201
  33. Sripa B, Mairiang E, Thinkhamrop B, et al (2009). Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology, 50, 1273-81.
  34. Sripa B, Pairojkul C (2008). Cholangiocarcinoma: lessons from Thailand. Cur Opin Gastroenterol, 24, 349-56. https://doi.org/10.1097/MOG.0b013e3282fbf9b3
  35. Sripa B, Thinkhamrop B, Mairiang E, et al (2012b). Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis, 6, e1654. https://doi.org/10.1371/journal.pntd.0001654
  36. Subrungruanga I, Thawornkunob C, Chawalitchewinkoon-Petmitrc P, et al (2013). Gene expression profiling of intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev, 14, 557-63. https://doi.org/10.7314/APJCP.2013.14.1.557
  37. Wang H, Zhang Z, Chu W, et al (2005). Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J Clin Endocrinol Metab, 90, 1123-9. https://doi.org/10.1210/jc.2004-1606
  38. Wise C, Pilanthananond M, Perry BF, et al (2008). Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol, 14, 2986-9. https://doi.org/10.3748/wjg.14.2986
  39. Wu CW, Wang SR, Chao MF, et al (1996). Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol, 91, 1417-22.
  40. Wu Q, He XD, Yu L, et al (2012). The metabolic syndrome and risk factors for biliary tract cancer: a case-control study in China. Asian Pac J Cancer Prev, 13, 1963-9. https://doi.org/10.7314/APJCP.2012.13.5.1963

Cited by

  1. Current Insights on Cholangiocarcinoma Research: a Brief Review vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1307
  2. Association between IL-6 Gene (−174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk vol.22, pp.4, 2016, https://doi.org/10.1007/s12253-016-0073-6
  3. Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review vol.98, pp.6, 2018, https://doi.org/10.4269/ajtmh.17-0879
  4. Thinking beyond Opisthorchis viverrini for risk of cholangiocarcinoma in the lower Mekong region: a systematic review and meta-analysis vol.7, pp.1, 2018, https://doi.org/10.1186/s40249-018-0434-3